|
Carisma Therapeutics Inc (NASDAQ: CARM) |
|
Carisma Therapeutics Inc
CARM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Carisma Therapeutics Inc 's sales fell
by -11.55 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2960
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
Carisma Therapeutics Inc net loss decreased from $-43 millions, to $-25 millions in III. Quarter 2024,
• More on CARM's Growth
|
|
Carisma Therapeutics Inc realized a net loss in trailing twelve months.
Carisma Therapeutics Inc realized cash reduction of $ -1.37 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.13.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on CARM's Valuation
|
|
|
|
|
Carisma Therapeutics Inc realized net loss in trailing twelve months.
Carisma Therapeutics Inc realized cash outflow of $ -1.37per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.13.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on CARM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com